97377-96-3 Usage
Molecular structure
1-phenyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester has a complex molecular structure, which includes a cyclopentapyrazole ring fused with a tetrahydro ring, a phenyl group, and a carboxylic acid functionality.
Ethyl ester derivative
1-phenyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester is an ethyl ester derivative of 1-phenyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid, indicating the presence of an ester functional group formed by the reaction of the carboxylic acid with ethanol.
Cyclopentapyrazole derivative
The compound is derived from cyclopentapyrazole, a five-membered heterocyclic ring system containing nitrogen, which is known for its potential applications in medicinal chemistry.
Phenyl group
The presence of a phenyl group (a carbon ring with delocalized electrons) in the structure contributes to the compound's potential pharmaceutical applications, as phenyl groups are commonly found in many drugs due to their ability to influence biological activity.
Carboxylic acid functionality
The carboxylic acid group (-COOH) in the compound is an important functional group in medicinal chemistry, as it can participate in hydrogen bonding and coordinate with metal ions, which can affect the compound's biological activity and solubility.
Potential pharmaceutical applications
Due to its specific molecular structure and functional groups, 1-phenyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester may have potential uses in the pharmaceutical industry, such as in the development of new drugs or drug delivery systems.
Interest for further research
The complex structure and functional groups of 1-phenyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester make it a subject of interest for further research in both medicinal and synthetic chemistry, as understanding its properties and reactivity could lead to the discovery of new applications and insights into its potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 97377-96-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,3,7 and 7 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 97377-96:
(7*9)+(6*7)+(5*3)+(4*7)+(3*7)+(2*9)+(1*6)=193
193 % 10 = 3
So 97377-96-3 is a valid CAS Registry Number.
97377-96-3Relevant academic research and scientific papers
Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation
Yang, Wei,Li, Yingjun,Ai, Yong,Obianom, Obinna N.,Guo, Dong,Yang, Hong,Sakamuru, Srilatha,Xia, Menghang,Shu, Yan,Xue, Fengtian
, p. 11151 - 11164 (2019/12/27)
Dysregulation of the Wnt/β-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.
Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
-
, (2008/06/13)
The present invention provides novel compositions of matter and their therapeutic applications. More particularly, the present invention consists of novel cyclopentapyrazole and tetrahydroindazole compounds of formula XXX and their use as antiallergy agents, antiinflammatory agents or intermediates. STR1
